Prospective studies are needed to analyze whether prevention of hypoalbuminemia (e.g., by optimizing nutrition or replacing albumin) can minimize the risk for AKI in AML patients undergoing induction chemotherapy. The gene discussed is ALB; the disease is acute myeloid leukemia.